Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. (November 2017)

• Record Type: Journal Article
• Authors: Zhu, Roger C; Rattanakorn, Kirk; Pham, Steven; Mallam, Divya; McIntyre, Thomas; Salifu, Moro O; Youssef, Irini; McFarlane, Samy I; Vignesh, Shivakumar
• Is Part Of: Colorectal cancer. Volume 6:Number 1(2017)
• Page Start: 33
• Page End: 41
• Publication Date: 2017-11
• Subjects: African American -- Afro Caribbean -- colorectal cancer -- diabetes -- metformin -- survival; Colon (Anatomy) -- Cancer -- Periodicals; Rectum -- Cancer -- Periodicals; 616.994347
• DOI: 10.2217/crc-2017-0001
• Languages: English
• ISSNs: 1758-194X

Abstract

We assessed the association of metformin use with survival in colorectal cancer in a population consists mostly of African-American and Afro-Caribbean patients. We identified 585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent of disease. Overall, DMs with metformin use (D+M+) have better overall survival than both DMs without metformin use (D+M∼) and nondiabetics (D∼M∼), with a mean survival of 109.9 months compared with 95.7 and 106.1 months, respectively (log-rank p < 0.05). The use of metformin shows significant reduction of risk of mortality compared with nonusers (hazard ratio: 0.34; 95% CI: 0.15–0.81; p = 0.01). Use of insulin and status of diabetes did not have a significant impact on overall cancer survival.